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Angiogenesis is a mulit-step process by which new blood vessels are formed from
preexisting vasculature. It is a key rate limiting factor in tumor growth since new
blood vessels are necessary to increase tumor size. In this context it has been shown
that anti-angiogenic factors can be used in cancer therapy. Among the plethora of
heterocyclic compounds administered as anti-angiogenesis agents, pyrazoles constitute
one of the bottlenecks of this category. Currently, several pyrazole based compounds are
administered or are in Phase II and III trials and new targets emerge. It is highly possible
that the advent of the next two decades will lead to the discovery and use of additional
pyrazoles whose anti-angiogenic profile will position them in the forefront of the battle of
various malignancies. The present review is an attempt to focus on those pyrazoles that
arise as anti-angiogenesis agents commenting both on the chemistry and bioactivity that
these exhibit aiming to contribute to the perspectives that they hold for future research.
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INTRODUCTION
Azaheterocyclic compounds comprise a class of compounds that
have demonstrated significant biological activities against various
human diseases. Thus, their exploitation constitutes a constant
goal of manymedicinal chemistry groups implemented in the dis-
covery of new lead pharmaceutical compounds. Angiogenesis—
the formation of new blood vessels—is a multistep process that
involves a complex interplay between a plethora of soluble fac-
tors, cell surface receptors, and extracellular matrix components
(for first angiogenesis references see Algire and Chalkely, 1945;
Folkman et al., 1971). Although angiogenesis is related to various
physiological functions, an excessive or insufficient angiogene-
sis is connected with the appearance of diverse human diseases
including retinopathy, rheumatoid arthritis, psoriasis, heman-
gioma, cancer (Folkman, 1995) and atherosclerosis (Sacar and
Yaylali, 2011). For cancer particular, for which angiogenesis is
regarded as a key stage, its inhibition constitutes an effective
mechanism in slowing down tumor growth and malignancies.
The growth factors, angiogenic enzymes, endothelial spe-
cific receptors and the adhesion molecules which are involved
in the expansion of vasa vasorum are all potential therapeu-
tic targets. Amongst growth factors Vascular Endothelial Growth
Factor (VEGF) is the major pro-angiogenesis factor, which is
known to stimulate various steps of endothelial angiogenic
activity, such as proliferation, migration, differentiation into
vessel-like tubes (Leung et al., 1989). Its identification and promi-
nent position in the angiogenic process has converted VEGF
to an important therapeutic target. Fibroblast growth factors
(FGFs) are heparin binding proteins that are also involved in
the pathogenesis and subsequent progression of various cancer
types such as endometrial cancer (Lee and Secord, 2014). In
this view two other receptor tyrosine kinases and their ligands,
namely angiopoietin/TIE-2 and ephrinB2/EphB4, contribute to
later steps of vascular development like vessel branching and
maturation.
Antiangiogenic agents—as stated by Ribatti (2014)—may be
divided into two major categories: (a) indirect agents that block
the activity of angiogenic molecules, or the expression of their
receptors on endothelial cells, and (b) agents that directly affect
endothelial cell function or survival.
Thus, the discovery of specific anti-angiogenesis agents con-
stitutes an attractive therapeutic approach for the treatment of
these diseases leading to the development of new highly active
organic molecules. Therefore, the last decade several azahete-
rocyclic molecules have emerged as potent inhibitors of angio-
genesis (see references in main text). The clinical research has
demonstrated that research groups involved in anti-angiogenesis
drugs for cancer are on a critical standpoint considering that
these drugs’ therapeutic activity in patients has been substan-
tially lower than expected based on preclinical findings. In this
context is essential to develop: (a) new compounds that will over-
come the efficiency problem at clinical trials and (b) new assays
to explore the dependency of individual tumors from any of these
angiogenic pathways.
Among many azaheterocyclic structural entities, our group
has devoted substantial effort to the preparation of pyrazole
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and isoxazole derivatives that might possess anti-angiogenic
(Christodoulou et al., 2010; Tzanetou et al., 2012) and antipro-
liferative activity (Tzanetou et al., 2014). Our main goal was and
still is to use commercially easily available molecules on which
these azaheterocycles can be built upon and subsequently tested
for their activity. Intrigued by our experience on the synthesis and
bioactivity of such type of heterocycles, we herein present selected
contemporary works on pyrazolic compounds that have demon-
strated anti-angiogenic activity. In this view the reader is invited
to revisit these research works and assess future perspectives of
substituted pyrazoles in the anti-angiogenesis domain.
PYRAZOLES SYNTHESIS
The condensation of hydrazines with various 1,3-diketones con-
stitutes the most common synthetic procedure for the con-
struction of the pyrazole backbone, since initial methods not
involving the 1,3-diketones require the adaptation of additional
synthetic steps (Aggarwal et al., 2003; Bishop et al., 2004;
Bhat et al., 2005). Other popular synthetic approaches are the:
(a) 1,3-dipolar cycloaddition of diazo compounds with alkynes
and (b) the reaction of α,β-unsaturated aldehydes and ketones
with hydrazines. Pyrazole derivatives can also be prepared by
the palladium-catalyzed four-component coupling of a terminal
alkyne, hydrazine, carbon monoxide under ambient pressure and
an aryl iodide as was recently reported by Ahmed et al. (2005).
In 2012 the formation of substituted pyrazoles was reported by
Panda and Jena (2012) using as substrates diarylhydrazones and
vicinal diols, catalyzed by iron chloride. Xion et al. reported also
the CuI-catalyzed coupling of N-acyl-N ′-substituted hydrazines
with aryl iodides affords N-acyl-N′,N′-disubstituted hydrazines
regioselectively (Xiong et al., 2012). Pyrazolopyrimidnes’—an
important class of pyrazole derived compounds with pronounced
biological action—synthesis is vastly described in the bibliog-
raphy and still attracts the interest of researchers (for a recent
reference see Colombo et al., 2014). Additionally pyrazoles are
synthesized by “elegant” approaches and incorporated in var-
ious fused core structures (Churruca et al., 2013), aiming to
enhance their activity by modulating specific targets. In view of
the importance of pyrazoles their synthesis has been efficiently
reviewed by many research groups (Kumar and Jayaroopa, 2014);
in the contemporary reviews apart from the synthetic pathways,
medicinal chemistry groups describe the bioactive profile of the
compounds (Chauhan and Kumar, 2013). Moreover Kumar et al.
described with clarity natural products containing pyrazole moi-
ety that have demonstrated significant bio-activity (Kumar et al.,
2013b). The latter can be a key component in the efforts to explore
and exploit chemical structures of bioactive natural products that
might lead to compounds that will improve treatment or ideally
cure patients.
THE HEREIN REPORTED PYRAZOLES
Pyrazolopyrimidines constitute the major pyrazole derivatives
that have been investigated for anti-angiogenic action and
selected works of the last 4 years are herein reported, though
the medicinal attributes of this class was successively reviewed by
Chauhan and Kumar (2013). In this context, emphasis is given
to selected works and endeavors not reviewed until now. Most
of pyrazolopyrimidines are kinase inhibitors which have been
shown to play an important role in the inhibition of VEGF driven
angiogenesis. Substituted, structurally flexible pyrazoles also pos-
sess a significant position amongst anti-angiogenic promising
compounds. This category of compounds is exemplified by the
current anti-angiogenic drug celecoxib, whose synthetic endeav-
ors are presented below and reference to its bioactivity is also
commented. Other pyrazole derivatives are alsomentioned in this
review article.
ANTI-CANCER PYRAZOLES
Pyrazoles that exhibit anti-cancer activity have been reviewed by
Chauhan et al. (2014). As correctly stated by the authors liter-
ature survey revealed that various N-substituted pyrazoles have
been implemented as antileukemic, antitumor, antiproliferative,
anti-angiogenic, DNA interacting, proapoptotic, autophagy, and
antitubulin agents. Moreover these compounds are capable to
exert remarkable anti-cancer effects through inhibition of differ-
ent types of enzymes, proteins and receptors which play critical
role in cell division. In this context the authors focused on the
recent developments in pyrazoles along with their structure-
activity relationship (SAR) that actually provides a good basis on
how structures are related with binding to various receptors and
how these compounds interplay with multiclass inhibitors. From
this work it is evident that structural modifications of various
pyrazoles have provided pharmacophore structures with medic-
inal interest and will probably continue to provide structural
frameworks for further anticancer drugs development.
PYRAZOLOPYRIMIDINES
TAK-593
TAK-593 a pyrazolo carboxamide (substituted pyrazolo carbox-
amide), discovered and synthesized by a research group of a
Japanese pharmaceutical company, is a highly potent VEGFR2
kinase inhibitor (Miyamoto et al., 2013). Molecular details for
these imidazo[1,2-b]pyridazine derivatives are reported in this
paper showing the crystal structure of a similar to TAK-593
derivative in complex with VEGFR2. This compound and TAK-
593 differ in the substitution pattern of the central phenyl
group (TAK-593 is methyl substituted at position 2 of the ring).
Indicatively, the N1-nitrogen of the imidazo[1,2-b]pyridazine
core interacts with the NH proton of Cys919; the CH proton at
the 8-position of the core forms a CH· · · O hydrogen bond with
the carbonyl group of Glu917, while the cyclopropane moiety
is suitably located in the solvent accessible region. The observa-
tion of a small hydrophobic pocket around the central phenyl
ring, indicated the possibility of introducing a substituent on the
phenyl moiety resulting in the synthesis of a series of substituted
derivatives, including the bioactive molecule of TAK-593. Hence,
from molecular docking standpoint the behavior of these com-
pounds into the VEGFR2 is fully rationalized. Furthermore, its
biochemical characterization was reported by Iwata et al. (2011).
Kinase selectivity profiling revealed that this compound inhibited
tyrosine kinases from the VEGFR and platelet-derived growth
factor receptor (PDGFR) families. Two years later, the synthe-
sis of this compound was published; it was based on previously
reported work of this group on pyridazine molecules that also
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functioned as VEGFR2 kinase inhibitors (see Miyamoto et al.,
2013 and references therein). Briefly, the preparation comprises
of four synthetic steps involving as starting material an iodopy-
ridazine. The major step of this pathway is the transformation of
the latter to an imidazopyridazine. The end molecule displayed
an IC50 value of 0.95 nM. Noteworthy it strongly suppressed pro-
liferation of VEGF-stimulated human umbilical vein endothelial
cells with a very low IC50 of 0.30 nM. The above findings pos-
tulate that TAK-593 is a lead compound and if systematically
alter its structure—based on detailed docking study—different
compounds can be yielded that are more effective and present
possibly fewer side effects (for improvement of lead compounds
see chapter 5 in Smith, 2013).
Pyrazolo[3,4-d] pyrimidines active on zebrafish model
A combined targeted/phenotypic approach for the rapid identifi-
cation of novel antiangiogenic compounds within in vivo efficacy
was developed by Radi et al. (2012). Considering the important
role played by the proto-oncogene tyrosine-protein kinase (c-Src)
in the regulation of tumor angiogenesis, an in-house library of c-
Src inhibitors was subjected to a sequential screening approach.
Firstly, the authors applied a virtual docking and scoring proce-
dure by submitting the VEGFR2 to a high throughput docking
protocol (in silico screening on VEGFR2) so as to sufficiently
select molecules for screening, considering that this approach is
more robust the than pharmacophore based methods. The best
compounds—which belonged to the pyrazolopyrimidines class
(e.g., see compound 1, Figure 1)—were then subjected in in vitro
screening on HUVEC cells, ADME profiling, formulation and
in vivo testing on a zebrafish model. Thus, a promising antiangio-
genic candidate, compound 1, able to interfere with the vascular
growth of a zebrafishmodel at lowmicromolar concentration was
identified.
An urea pyrazolo[3,4-d]pyrimidine
Many research groups try to “invest” on currently active com-
pounds in order to prepare derivatives with enhanced activity.
In a paper published in 2013 the structural optimization of a
hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-
phenyl)-3-(3-methoxyphenyl)urea, which exhibited inhibitory
activity but low potency against FMS-like tyrosine kinase 3
(FLT3) and VEGFR2, was described (Yang et al., 2013). The
authors developed a series of pyrazolo[3,4-d]pyrimidine deriva-
tives based on structural modifications of specific atoms or
subgroups, assisted by structure-activity relationship (SAR) anal-
ysis using cell—and transgenic-zebrafish-based assays. All of the
target compounds were prepared from the general intermedi-
ate 4-chloro-1H-pyrazolo[3,4-d]pyrimidine, which was obtained
through reaction of phosphorus oxychloride with a commercially
available pyrazolopyrimidinone. The latter was reacted with var-
ious chlorine substituents whose synthesis is also reported in
distinct schemes. These efforts led to the discovery of a number
of compounds that exhibited both high potency against FLT3-
driven human acute myeloid leukemia (AML)MV4-11 cells and a
considerable anti-angiogenic effect in transgenic-zebrafish-based
assays. One pyrazolo urea derivative, which exhibited the high-
est activity in preliminary in vivo anti-AML assays, was chosen
for further anti-AML studies. The studies revealed that this com-
pound can serve as multikinase inhibitor that potently inhibits
FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a
once-daily dose of compound 33 at 10mg/kg for 18 days led to
complete tumor regression without obvious toxicity. From bioac-
tivity point of view, it is evident that the presence of an oxygen
atom as a linker favors bioactivity and should be regarded in fur-
ther synthetic efforts (suggesting that the phenoxy group should
be maintained). Moreover substitution of the N-1 position is not
beneficial for the activity, while discussion on the role of bridge
groups and ring B moiety can help as well in the design of new
molecules.
Trisubstituted pyrazolo[4,3-d]pyrimidines
In the frames of exploiting small molecular inhibitors of tyrosine
kinase receptors Weitensteiner et al. have developed active trisub-
stituted pyrazolo[4,3-d]pyrimidines as novel anti-angiogenic
compounds (Weitensteiner et al., 2013). Their synthesis was
based on a condensation step of a methylsulfone compound
with the respective amine. All seven tested compounds inhib-
ited endothelial cell proliferation with IC50 values ranging from
1 to 18μM [compound LGR-1404(R) is depicted in Figure 1].
The latter was not attributed to cytotoxicity, since none of them
showed acute cytotoxic effects on endothelial cells at a con-
centration of 10μM. The three most potent compounds also
inhibited cell migration, chemotaxis and tube formation. Apart
from the efficiency in in vitro testing the antiangiogenic potency
of these compounds was tested with the in vivo chorioallan-
toic membrane (CAM) assays. The three compounds completely
eliminated VEGF induced vessel formation. Again, structural
modifications can provide improved compounds conditioning
that appropriate molecular modeling study accompanies the syn-
thesis. Specifically, targeted elongation of the side chain bearing
the alcohol group or alkyl substitution of the amines can function
as synthetic alternatives to the pursuit of LGR-1404 analogs.
SMALL KINASE INHIBITOR
Novartis group developed novel small molecular weight kinase
inhibitors (Martiny-Baron et al., 2010). Amongst them NVP-
BHG712 (see structure in Figure 1) inhibited erythropoietin-
producing hepatocellular carcinoma, EphB4 kinase activity in the
low nanomolar range, showing—in cellular assays—high selec-
tivity for targeting the EphB4 kinase when profiles against other
kinases in biochemical as well in cell based assays. Design of NVP-
BHG712 was reinforced by molecular modeling of the kinase
domain of EphB4 and further optimized using structure-activity-
relationship data based on inhibition of EphB4 autophosphory-
lation in a cellular assay. Its synthesis has been described in a
patent (see pertinent reference into the document). At in vivo level
this molecule inhibits VEGF driven vessel formation, while it has
only little effects on VEGF receptor activity in vitro or in cellular
assays. From the above is evident that further exploitation of this
structure should and will probably follow.
CELECOXIB
Celecoxib is a tricyclic compound that encompasses a pyrazole
ring (see Figure 1). This compound acts as an excellent selec-
tive non-steroidal anti-inflammatory agent, which inhibits the
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FIGURE 1 | Key structures of active anti-angiogenic pyrazoles.
enzyme cyclooxygenase-2 (COX-2). Its synthesis and develop-
ments of it, have been efficiently reviewed by Kumar et al.,
demonstrating that the main synthetic step is the condensation
of 1,3-diketones with hydrazines (Kumar et al., 2013a). In this
review improvements on the “classical condensation reaction” as
well as development of prodrugs and derivatives of celecoxib are
also presented.
The association of celecoxib with angiogenesis has been
reported by many groups. In this context Wei et al. reported
in 2004 that celecoxib inhibits VEGF expression and reduces
angiogenesis and metastasis of human pancreatic cancer via sup-
pression of Sp1 transcription factor activity (Wei et al., 2004).
Additionally, and in contrast to its previously mentioned anti-
angiogenic profile, researchers have shown that celecoxib can
induce VEGF expression and tumor angiogenesis (Xu et al.,
2011).
PYRAZOLOBENZODIAZEPINES
In 2011 the preclinical evaluation of a novel multi-targeted agent
R1530 (see structure in Figure 2) was reported by a group of
Hoffman-La Roche (Kolinsky et al., 2011). The anti-proliferative
activity of this compound was tested in a range of human tumor,
endothelial and fibroblast cell lines. R1530 exhibited activity
against tumor models in vitro and in vivo leading to the efficient
angiogenesis inhibition. The synthesis was rationalized on the di-
substitution at 7,8 positions of the fused benzene rings aiming to
improve on the kinase inhibitory activities since an amine deriva-
tive previously synthesized (Liu et al., 2010) exhibited high kinase
inhibitory activity however its ADMET (absorption, distribution,
metabolism, and excretion) profile discouraged the human eval-
uation. The crystal structure of one analog with cyclin-dependent
kinase 2 (CDK2) receptor as reported by Liu et al., showed that
pyrazolobenzodiazepine core occupies the same site as the adeno-
sine of ATP, and makes three critical H-bonds to the hinge region.
Extensive discussion on the receptor binding sites is given in
that paper. Later in 2013 same group reported the synthesis of
R1530 and precursor of it, while they explained the rationale
behind synthesis and structural modifications that took place (Liu
et al., 2013). Synthesis was based initially on a condensation of
a substituted aniline with a benzonitrile. The imine intermedi-
ate was transformed to a corresponding diazepinone and with a
three step synthesis to the final pyrazolobenzodiazepine. In paral-
lel the authors reported a convergent synthesis of R1530. Finally
in that work R1530 as compared to a monosubstituted counter-
part showed stronger inhibitory activities against angiogenesis-
related receptor tyrosine kinases, indicating the feasibility of
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FIGURE 2 | Diamino pyrazoles, a pyrazolobenzodiazepine, copper and ferrocenyl complexes.
improving potency and selectivity for the angiogenesis-related
kinases.
COPPER COMPLEX OF SALICYLALDEHYDE PYRAZOLE
A work published in 2010 was focused on complexes of cop-
per and salicylaldehyde pyrazole hydrazine, which belong to the
family of trisubstituted pyrazoles (see structure of Cu-16 com-
plex in Figure 2) (Fan et al., 2010). The latter was an outcome of
the increased anti-cancer activities of copper complexes (Brewer,
2001) and the anti-proliferative profile of previously synthesized
pyrazoles (Chen et al., 2008; Xia et al., 2008). Syntheses of these
complexes were based on published procedures before 2010 (Xia
et al., 2008; Fan et al., 2009). From compounds synthesized the
Cu-16 complex bearing a tert-butyl moiety promoted apoptosis
in H322 cells through elevating the protein level of integrin β4.
KI-10F AN ANTICANCER, ANTI-ANGIOGENESIS AGENT
A novel pyrazole derivative KI-10F [2-(4-(2-(4-(Dimethyl-
amino)phenyl)pyridin-4-yl)-5-(3-methoxy-5-methylphenyl)-1H-
pyrazol-1-yl), structure in Figure 1] acetonitrile was developed
and evaluated in human colon cancer cells (Hong et al., 2012).
Its synthesis is not described (only the formation of the HCl
salt) into the paper however the specific compound inhibited
angiogenesis both in vivo and in vitro, categorizing it as a
chemotherapeutic candidate. Specifically KI-10F strongly sup-
pressed the growth of human colon cancer cells and induced
apoptosis by increasing the proportion of sub-G1 presenting
apoptotic cells as well as causing cycle arrest at the G2/M phase.
Moreover it decreased expression of HIF-1α and VEGF, and the
HUVEC tube formation and migration, thus it inhibited the
angiogenesis process.
ENMD-2076
In the frame of constantly growing number of small molecules
and antibody kinase inhibitors that have entered the global mar-
ket for the battle of various cancer forms a research group pub-
lished a preclinical development of a new azaheterocycle ENMD-
2076 (see Figure 1) with pronounced antiangiogenesis and
antiproliferative action (Fletcher et al., 2011). In this regard, the
authors proceeded to the synthesis of ENMD-2076 according to
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patented procedure (PATENT-11) and then assessed its biological
activity. ENMD-2076 is a well-tolerated, orally active multi-target
kinase inhibitor with a unique antiangiogenic/antiproliferative
profile and provides strong preclinical support for use as a thera-
peutic for human cancers (Diamond et al., 2013; Matulonis et al.,
2013).
DIAMINOPYRAZOLES
CAN508 is a 3,5-diamino pyrazole (see Figure 2) that has been
developed as an anticancer drug but has also been shown to
inhibit angiogenesis (Krystof et al., 2011). This molecule rep-
resents a novel approach on anti-angiogenesis drug candidates
which focuses on small simplified pyrazoles. The latter might
open new frontiers on the efficient preparation of a plethora of
small substituted pyrazoles. CAN508 synthesis has been reported
in a patent and it also appears in a publication of Krystof
et al. (2006). Briefly, it starts with a diazotization of arylamines
and finalizes with a cyclocondensation of these hydrazones with
hydrazines to furnish the desired compounds. CAN508 inhib-
ited endothelial cell migration and tube formation. Its high
selectivity toward the positive transcription elongation factor b
(P-TEFb), suggested that P-TEFbmay be a possible target for anti-
angiogenic therapy. The same group in 2014 published a work on
a novel member of this class of compounds; AAP1742 (Figure 2)
was found to inhibit cyclic-dependent kinases 9 (CDK9) and
reduced the viability of multiple myeloma cell lines in low
micromolar concentrations (Jorda et al., 2014).
FERROCENYL PYRAZOLINES
Recently novel ferrocene-containing N-acetylated-2-pyrazoline
compounds were studied for in vitro inhibition of angiogenesis
and human lung cancer growth (Bostancioglu et al., 2013). The
compounds of interest were synthesized based on bibliographic
procedures (see Bostancioglu et al., 2013 and references therein).
The final tested products were prepared by reaction of interme-
diate chalcones with hydrazine hydrate to afford N-acetylated
products. For testing two cell lines were used, a human non-
small-cell lung cancer cell line (A549) and a human umbilical
vein endothelial cell line. The cytotoxic activity was assessed
by the methyl thiazol tetrazolium assay (MTT), apoptotic by
4,6-diamidinophenylindole and F-actin staining, antitumoral by
colony forming ability assay and antiangiogenic activities by tube
formation. The dose dependent manner of compounds activ-
ities was revealed by the assays with N-acetyl-3-(2-thienyl)-5-
ferrocenyl-2-pyrazoline being the most potent in inhibition of
capillary vessel formation (see structure in Figure 2). The lat-
ter can be used in the development of therapeutic agents for
angiogenic-related diseases and cancer.
CONCLUDING REMARKS
Pyrazole molecules are in the forefront of organic chemistry
due to their capacity to encompass various substituents which
in sequence administer—to the synthesized molecules—unique
medicinal properties. In this regard the interest on their chem-
istry will remain and possibly increase due to the need of more
1http://patents.justia.com/patent/7563787
bioactive heterocylcles. As regards their angiogenesis implication
it is a logical outcome after their initial implication in the anti-
cancer drug portfolio which embraces angiogenesis. In that frame
researchers have to concentrate on: (a) already reported anti-
angiogenic pyrazoles, such as TAK-593 which exhibited activity
at the nanomolar range, and pursue structural improvements
that will lead to molecules with enhanced bioactivity and will
be devoid of toxic side effects (b) explore pyrazolic compounds
that have been developed to target other diseases but might pos-
sess anti-angiogenic action as well and (c) develop new pyrazole
derivatives that will target the angiogenic cascade, incorporating
novel or existing natural products’ derived heterocycles.
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